면역항암제(IO) 시장 : 테마별 인텔리전스

Abstract

This report includes coverage of immuno-oncology overview, trends, value chain, leading marketed and pipeline products, market analysis, regulatory landscape and market access, opportunities, challenges, and unmet needs, commercial assessment - major current and future players in the immuno-oncology field.

The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer. Checkpoint modulation to remain the most valuable IO sector. 2022-23 has seen some IO success, but no major IO breakthrough has happened. Personalized treatment using biomarkers, therapeutic options for checkpoint refractory patients, and the high cost of therapy remain as unmet needs.

Key Highlights

Forecast includes 8 countries

Forecast covers 2022-2028

Seven markets are extrapolated, obtaining a 15-market value for all GBM therapeutics

Scope

• This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.

Reasons to Buy

OBTAIN IMMUNO-ONCOLOGY MARKET ASSESSMENT AND FORECAST ACROSS MULTIPLE REGIONS

GAIN INSIGHT INTO PROMISING EARLY STAGE APPROACHES

Our indication specific forecast models answer questions such as -

• What is the target patient pool for cell & gene therapies in each cancer indication?
• Which patient groups are more likely to receive these therapies?
• What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
• What is the anticipated breakdown between autologous and allogeneic cell therapies?
• When will cell & gene therapies launch in each market?
• What is the total market value projected for the forecast end, in 2031?

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Related Reports

2. Executive Summary

3. Immuno-Oncology Overview

• 3.1. What is IO?
• 3.2. What is Immuno-oncology According to Regulators?
• 3.3. Most Important Milestones of Immuno-oncology Development Globally
• 3.4. Key Twitter Chat

4. Trends

• 4.1. Industry Trends - Bispecific Antibodies
• 4.2. Industry Trends - Cancer Vaccines
• 4.3. Industry Trends - Cell Therapies
• 4.4. Industry Trends - Checkpoint Modulators
• 4.5. Industry Trends - Cytokines
• 4.6. Industry Trends - Oncolytic Viruses
• 4.7. Regulatory Trends

5. Value Chain

• 5.1 Immuno-oncology Value Chain
• 5.2 Bispecific Antibodies
• 5.3 Cancer Vaccines
• 5.4 Cell Therapies
• 5.5 Checkpoint Modulators
• 5.6 Next-generation Cytokines
• 5.7 Oncolytic Viruses
• 5.8 Immuno-oncology in Clinical Trials

6. Marketed Products

• 6.1. Immuno-Oncology Marketed Products in the 8MM
• 6.2. Total Market Size for IO Agents
• 6.3. 10 Highest-Grossing IO Treatments in 2022
• 6.4. Leading Checkpoint Modulators in the 8MM
• 6.5. Leading BiTEs in the 8MM
• 6.6. Leading Cancer Vaccines and Oncolytic Viruses in the 8MM
• 6.7. Leading Cell Therapies in the 8MM

7. Pipeline Products

• 7.1. IO Pipeline Products in the 8MM
• 7.2. Future Outlook of IO Agents, According to High-Prescribing Physicians
• 7.3. Consensus Forecast Sales for the Top Three Pipeline Candidates
• 7.4. The Forecast Highest-Grossing Bispecific Antibody Products
• 7.5. The Forecast Highest-Grossing Vaccine Products
• 7.6. The Forecast Highest-Grossing Cell Therapy Products
• 7.7. The Forecast Highest-Grossing Checkpoint Modulator Products
• 7.8. The Forecast Highest-Grossing Cytokine Products
• 7.9. The Forecast Highest-Grossing Oncolytic Virus Products

8. Market Analysis

• 8.1. Market Analysis and Forecast of the Six Classes of IO Agents
• 8.2. Top 10 Strategic Partnership Deals of the Last Decade by Size in the IO Space
• 8.3. Latest Strategic Partnership Deals in the IO Space
• 8.4. Top 10 Mergers and Acquisitions that Include IO Assets: 2018-2023
• 8.5. Latest Mergers and Acquisitions that Include IO Assets

9. Regulatory and Market Access

• 9.1. IO in Clinical Trials
• 9.2. Endpoints in IO Clinical Trials - KOL Perspective
• 9.3. Challenges in IO Clinical Trials - KOL Perspective
• 9.4. Regulatory and Market Access - US
• 9.5. Regulatory and Market Access - EU
• 9.6. Regulatory and Market Access - Japan
• 9.7. Regulatory and Market Access - China
• 9.8. Early Access Schemes
• 9.9. Barriers to Access According to High Prescribers

10. Opportunities, Challenges, and Unmet Needs

• 10.1. Bispecific Antibodies
• 10.2. Cancer Vaccines
• 10.3. Cell Therapies
• 10.4. Checkpoint Modulators
• 10.5. Cytokines
• 10.6. Oncolytic Viruses
• 10.7. Clinical Unmet Needs in IO - Gap Analysis
• 10.8. Commercial Unmet Needs in Immuno-oncology - Gap Analysis
• 10.9. Unmet Needs - KOL Perspective
• 10.10 . Unmet Needs According to High Prescribers
• 10.11 R&D Strategies
• 10.12 Opportunities for the Industry - Modern Approaches & Collaboration
• 10.13 Closing Remarks - In Their Words

11. Companies

• 11.1. Drug Development Scorecard
• 11.2. Current Major Players - Novartis
• 11.3. Current Major Players - Merck & Co.
• 11.4. Current Major Players - Gilead Sciences
• 11.5. Current Major Players - Roche
• 11.6. Current Major Players - BMS
• 11.7. Current Major Players - AstraZeneca
• 11.8. Current Major Players - Sanofi
• 11.9. Current Major Players - Amgen
• 11.10. Current Major Players - Dendreon Pharmaceuticals
• 11.11. Current Major Players - Legend Biotech
• 11.12. Current Major Players - Johnson & Johnson
• 11.13. Current Major Players - Daiichi-Sankyo
• 11.14. Current Major Players - Kite
• 11.15. Current Major Players - Regeneron
• 11.16. Future Players Based on Pipeline Strength - Genmab
• 11.17. Future Players Based on Pipeline Strength - Iovance Therapeutics
• 11.18. Future Players Based on Pipeline Strength - Replimune
• 11.19. Future Players Based on Pipeline Strength - VBI Vaccines
• 11.20. Future Players Based on Pipeline Strength - Jounce Therapeutics
• 11.21. Future Players Based on Pipeline Strength - Oncosec
• 11.22. Future Players Based on Pipeline Strength - Abbvie
• 11.23. Future Players Based on Pipeline Strength - BioNTech
• 11.24. Future Players Based on Pipeline Strength - Greenwich LifeSciences
• 11.25. Future Players Based on Pipeline Strength - CRISPR Therapeutics
• 11.26. Future Players Based on Pipeline Strength - Allogene Therapeutics
• 11.27. Future Players Based on Pipeline Strength - Xilio Therapeutics
• 11.28. Future Players Based on Pipeline Strength - Candel Therapeutics

12. Appendix

• 12.1. Sources
• 12.2. Primary Research
• 12.3. Key Themes Impacting the Pharmaceutical Industry
• 12.4. Our Thematic Research Methodology
• 12.5. About the Authors

13. Contact Us